Assessing the Competing Risks of Loss to Follow-up and Mortality Among Adults Receiving Antiretroviral Therapy in Northern Ghana: Application of the Fine-Gray Subdistribution Hazard Model
This study of adults receiving antiretroviral therapy in Northern Ghana reveals that loss to follow-up is a more frequent outcome than mortality, with travel distance significantly hindering retention while baseline weight, sex, and ART regimen are key predictors of death.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Keeping a person alive with HIV today relies on a simple but demanding routine: taking daily medication and returning to a clinic for regular checkups. This cycle of care is what keeps the virus suppressed and allows people to live long, healthy lives. However, in many parts of the world, keeping patients in this cycle is incredibly difficult. People stop coming to the clinic for reasons that have nothing to do with the medicine itself. They might move away, run out of money for travel, or simply lose hope. When they stop showing up, doctors call this "loss to follow-up." At the same time, some patients unfortunately pass away. These two outcomes—disappearing from care and dying—are deeply connected. If a person dies, they can no longer disappear from the clinic; if they disappear, the clinic can no longer see if they have died. This creates a statistical puzzle. Traditional ways of counting these events often treat them as separate, unrelated things, which can lead to a distorted view of how many people are actually lost to care versus how many are dying. To get a true picture of the situation, researchers need a method that understands these events are competing against each other, where one event prevents the other from being observed.
In a recent study focused on Northern Ghana, a team of researchers tackled this puzzle to understand what happens to adults starting antiretroviral therapy in that region. They looked at the records of 329 adults who began treatment at the Nalerigu Baptist Medical Centre between 2013 and 2019. Instead of using standard counting methods, they applied a specialized statistical approach designed specifically for situations where two bad outcomes compete. This method allowed them to calculate the true probability of a patient either leaving care or dying over time, without one outcome hiding the other. The researchers wanted to know not just how many people were lost, but what specific factors made it more likely for a person to fall out of care or pass away. They examined details like how far a patient lived from the clinic, their weight when they started treatment, their gender, and the specific type of medication they received.
The results revealed a stark reality: losing contact with the clinic was far more common than death. Over the course of three years, about half of the patients in the study had stopped attending their appointments, while roughly one in six had died. The most significant barrier to staying in care was simply distance. Patients who lived more than ten kilometers from the clinic were much more likely to disappear from the system than those who lived closer. The journey itself, with its associated costs and time, acted as a powerful force pushing people away from treatment. Surprisingly, the study also found that patients who started treatment with a higher body weight were more likely to be lost to follow-up. This seems counterintuitive, as better weight usually signals better health, but the researchers suggest that those who feel healthier might feel less urgency to visit the clinic regularly, or they may become busier with work and other life demands.
When the researchers looked at who was most likely to die, a different set of factors emerged. Being male was a strong predictor of mortality, with men facing a significantly higher risk of death than women. The type of medication also mattered greatly; patients taking a specific drug called efavirenz had a much lower risk of dying compared to those taking nevirapine. Additionally, a higher starting weight was protective against death, suggesting that better nutritional status helps the body survive the early, difficult stages of treatment. The study also confirmed that the statistical method they used was essential. When they compared their results to older, simpler methods, they found that the traditional approaches would have missed the true impact of travel distance on retention and might have underestimated the risks for certain groups.
The study concludes that to save lives and keep treatment programs working, health officials must look beyond just the medicine. The physical distance a patient must travel is a critical factor that can determine whether they stay alive and healthy or fall out of the system. While better nutrition and specific drug choices help patients survive, the logistics of getting to the clinic remain a major hurdle. The findings suggest that bringing care closer to people, perhaps through community-based programs or mobile clinics, could be just as important as the drugs themselves. By understanding that the risk of disappearing and the risk of dying are linked, health programs can design better support systems to ensure that the people who need treatment the most are the ones who actually receive it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.